Cynthia Taylor
Payments from drug & device makers
Across 308 payments — averaging $14.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$710
- Otsuka America Pharmaceutical, Inc.$664
- Alkermes, Inc.$482
- AbbVie$389
- Teva Pharmaceuticals USA, Inc.$363
- plus $719 from 11 others
What the payments were for
- Food & beverage$4,345100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 65 | $1,017 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 88 | $710 |
| Otsuka America Pharmaceutical, Inc. | 35 | $664 |
| Alkermes, Inc. | 29 | $482 |
| AbbVie | 20 | $389 |
| Teva Pharmaceuticals USA, Inc. | 30 | $363 |
| Neurocrine Biosciences, Inc. | 15 | $244 |
| Indivior Inc. | 10 | $188 |
| Vanda Pharmaceuticals Inc. | 4 | $80 |
| Bayer | 3 | $56 |
| Braeburn Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
| Exact Sciences | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Organogenesis Inc. | 1 | $13 |
How this compares
$4,345 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 65 | $63,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $25,689 |
| JardianceEmpagliflozin | 32 | $20,233 |
| XareltoRivaroxaban | 34 | $18,158 |
| EliquisApixaban | 27 | $15,140 |
| OzempicSemaglutide | 13 | $12,114 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 83 | $8,999 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 245 | $7,150 |
| JanuviaSitagliptin Phosphate | 11 | $6,860 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,421 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,679 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $5,578 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $5,294 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $4,941 |
| MyrbetriqMirabegron | 11 | $4,775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $32 | $63,84565 claims |
| Johnson & JohnsonXarelto | $1,017 | $18,15834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Akron
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.